FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2148525121> ?p ?o ?g. }

• W2148525121 endingPage "1136" @default.
• W2148525121 startingPage "1128" @default.
• W2148525121 abstract "ObjectiveWe propose that the fetal heart is highly resilient to hypoxic stress. Our objective was to elucidate the human fetal gene expression profile in response to simulated ischemia and reperfusion to identify molecular targets that account for the innate cardioprotection exhibited by the fetal phenotype.MethodsPrimary cultures of human fetal cardiac myocytes (gestational age, 15–20 weeks) were exposed to simulated ischemia and reperfusion in vitro by using a simulated ischemic buffer under anoxic conditions. Total RNA from treated and baseline cells were isolated, reverse transcribed, and labeled with Cy3 or Cy5 and hybridized to a human cDNA microarray for expression analysis. This analysis revealed a highly significant (false discovery rate, <3%) suppression of interleukin 6 transcript levels during the reperfusion phase confirmed by means of quantitative polymerase chain reaction (0.25 ± 0.11-fold). Interleukin 6 signaling during ischemia and reperfusion was assessed at the protein expression level by means of Western measurements of interleukin 6 receptor, the signaling subunit of the interleukin 6 receptor complex (gp130), and signal transducer of activated transcription 3. Posttranslational changes in the protein kinase B signaling pathway were determined on the basis of the phosphorylation status of protein kinase B, mitogen-activated protein kinase, and glycogen synthase kinase 3β. The effect of suppression of a prohypertrophic kinase, integrin-linked kinase, with short-interfering RNA was determined in an ischemia and reperfusion-stressed neonatal rat cardiac myocyte model. Endogenous secretion of interleukin 6 protein in culture supernatants was measured by enzyme-linked immunosorbent assay.ResultsHuman fetal cardiac myocytes exhibited a significantly lower rate of apoptosis induction during ischemia and reperfusion and after exposure to staurosporine and recombinant interleukin 6 compared with that observed in neonatal rat cardiac myocytes (P < .05 for all comparisons, analysis of variance). Exposure to exogenously added recombinant interleukin 6 increased the apoptotic rate in both rat and human fetal cardiac myocytes (P < .05). Short-interfering RNA-mediated suppression of integrin-linked kinase, a prohypertrophy upstream kinase regulating protein kinase B and glycogen synthase kinase 3β phosphorylation, was cytoprotective against ischemia and reperfusion-induced apoptosis in neonatal rat cardiac myocytes (P < .05).ConclusionsHuman fetal cardiac myocytes exhibit a uniquely adaptive transcriptional response to ischemia and reperfusion that is associated with an apoptosis-resistant phenotype. The stress-inducible fetal cardiac myocyte gene repertoire is a useful platform for identification of targets relevant to the mitigation of cardiac ischemic injury and highlights a novel avenue involving interleukin 6 modulation for preventing the cardiac myocyte injury associated with ischemia and reperfusion. We propose that the fetal heart is highly resilient to hypoxic stress. Our objective was to elucidate the human fetal gene expression profile in response to simulated ischemia and reperfusion to identify molecular targets that account for the innate cardioprotection exhibited by the fetal phenotype. Primary cultures of human fetal cardiac myocytes (gestational age, 15–20 weeks) were exposed to simulated ischemia and reperfusion in vitro by using a simulated ischemic buffer under anoxic conditions. Total RNA from treated and baseline cells were isolated, reverse transcribed, and labeled with Cy3 or Cy5 and hybridized to a human cDNA microarray for expression analysis. This analysis revealed a highly significant (false discovery rate, <3%) suppression of interleukin 6 transcript levels during the reperfusion phase confirmed by means of quantitative polymerase chain reaction (0.25 ± 0.11-fold). Interleukin 6 signaling during ischemia and reperfusion was assessed at the protein expression level by means of Western measurements of interleukin 6 receptor, the signaling subunit of the interleukin 6 receptor complex (gp130), and signal transducer of activated transcription 3. Posttranslational changes in the protein kinase B signaling pathway were determined on the basis of the phosphorylation status of protein kinase B, mitogen-activated protein kinase, and glycogen synthase kinase 3β. The effect of suppression of a prohypertrophic kinase, integrin-linked kinase, with short-interfering RNA was determined in an ischemia and reperfusion-stressed neonatal rat cardiac myocyte model. Endogenous secretion of interleukin 6 protein in culture supernatants was measured by enzyme-linked immunosorbent assay. Human fetal cardiac myocytes exhibited a significantly lower rate of apoptosis induction during ischemia and reperfusion and after exposure to staurosporine and recombinant interleukin 6 compared with that observed in neonatal rat cardiac myocytes (P < .05 for all comparisons, analysis of variance). Exposure to exogenously added recombinant interleukin 6 increased the apoptotic rate in both rat and human fetal cardiac myocytes (P < .05). Short-interfering RNA-mediated suppression of integrin-linked kinase, a prohypertrophy upstream kinase regulating protein kinase B and glycogen synthase kinase 3β phosphorylation, was cytoprotective against ischemia and reperfusion-induced apoptosis in neonatal rat cardiac myocytes (P < .05). Human fetal cardiac myocytes exhibit a uniquely adaptive transcriptional response to ischemia and reperfusion that is associated with an apoptosis-resistant phenotype. The stress-inducible fetal cardiac myocyte gene repertoire is a useful platform for identification of targets relevant to the mitigation of cardiac ischemic injury and highlights a novel avenue involving interleukin 6 modulation for preventing the cardiac myocyte injury associated with ischemia and reperfusion." @default.
• W2148525121 created "2016-06-24" @default.
• W2148525121 creator A5025479609 @default.
• W2148525121 creator A5027392912 @default.
• W2148525121 creator A5028087753 @default.
• W2148525121 creator A5028562399 @default.
• W2148525121 creator A5030577331 @default.
• W2148525121 creator A5039003434 @default.
• W2148525121 creator A5043927370 @default.
• W2148525121 creator A5052336708 @default.
• W2148525121 creator A5063716975 @default.
• W2148525121 creator A5064404027 @default.
• W2148525121 creator A5068855164 @default.
• W2148525121 creator A5082589131 @default.
• W2148525121 creator A5086568816 @default.
• W2148525121 creator A5089490285 @default.
• W2148525121 creator A5090048017 @default.
• W2148525121 date "2005-05-01" @default.
• W2148525121 modified "2023-09-27" @default.
• W2148525121 title "Cardioprotective stress response in the human fetal heart" @default.
• W2148525121 cites W1479831323 @default.
• W2148525121 cites W1533139940 @default.
• W2148525121 cites W1597588755 @default.
• W2148525121 cites W1779691448 @default.
• W2148525121 cites W1792813868 @default.
• W2148525121 cites W1866410257 @default.
• W2148525121 cites W1980899588 @default.
• W2148525121 cites W1980994248 @default.
• W2148525121 cites W2004549688 @default.
• W2148525121 cites W2013167680 @default.
• W2148525121 cites W2017240081 @default.
• W2148525121 cites W2022123949 @default.
• W2148525121 cites W2026318147 @default.
• W2148525121 cites W2029796081 @default.
• W2148525121 cites W2032554944 @default.
• W2148525121 cites W2033240402 @default.
• W2148525121 cites W2037870084 @default.
• W2148525121 cites W2051947267 @default.
• W2148525121 cites W2052012699 @default.
• W2148525121 cites W2052198538 @default.
• W2148525121 cites W2068094391 @default.
• W2148525121 cites W2068702627 @default.
• W2148525121 cites W2071968903 @default.
• W2148525121 cites W2085069795 @default.
• W2148525121 cites W2105014609 @default.
• W2148525121 cites W2110327133 @default.
• W2148525121 cites W2146021917 @default.
• W2148525121 cites W2157795344 @default.
• W2148525121 cites W2169233819 @default.
• W2148525121 cites W2169350835 @default.
• W2148525121 cites W2317845988 @default.
• W2148525121 cites W4294107304 @default.
• W2148525121 doi "https://doi.org/10.1016/j.jtcvs.2004.11.055" @default.
• W2148525121 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5328676" @default.
• W2148525121 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15867790" @default.
• W2148525121 hasPublicationYear "2005" @default.
• W2148525121 type Work @default.
• W2148525121 sameAs 2148525121 @default.
• W2148525121 citedByCount "31" @default.
• W2148525121 countsByYear W21485251212012 @default.
• W2148525121 countsByYear W21485251212013 @default.
• W2148525121 countsByYear W21485251212014 @default.
• W2148525121 countsByYear W21485251212015 @default.
• W2148525121 countsByYear W21485251212017 @default.
• W2148525121 countsByYear W21485251212018 @default.
• W2148525121 countsByYear W21485251212019 @default.
• W2148525121 countsByYear W21485251212020 @default.
• W2148525121 countsByYear W21485251212022 @default.
• W2148525121 crossrefType "journal-article" @default.
• W2148525121 hasAuthorship W2148525121A5025479609 @default.
• W2148525121 hasAuthorship W2148525121A5027392912 @default.
• W2148525121 hasAuthorship W2148525121A5028087753 @default.
• W2148525121 hasAuthorship W2148525121A5028562399 @default.
• W2148525121 hasAuthorship W2148525121A5030577331 @default.
• W2148525121 hasAuthorship W2148525121A5039003434 @default.
• W2148525121 hasAuthorship W2148525121A5043927370 @default.
• W2148525121 hasAuthorship W2148525121A5052336708 @default.
• W2148525121 hasAuthorship W2148525121A5063716975 @default.
• W2148525121 hasAuthorship W2148525121A5064404027 @default.
• W2148525121 hasAuthorship W2148525121A5068855164 @default.
• W2148525121 hasAuthorship W2148525121A5082589131 @default.
• W2148525121 hasAuthorship W2148525121A5086568816 @default.
• W2148525121 hasAuthorship W2148525121A5089490285 @default.
• W2148525121 hasAuthorship W2148525121A5090048017 @default.
• W2148525121 hasBestOaLocation W21485251211 @default.
• W2148525121 hasConcept C126322002 @default.
• W2148525121 hasConcept C134018914 @default.
• W2148525121 hasConcept C153911025 @default.
• W2148525121 hasConcept C172680121 @default.
• W2148525121 hasConcept C184235292 @default.
• W2148525121 hasConcept C2779234561 @default.
• W2148525121 hasConcept C54355233 @default.
• W2148525121 hasConcept C62478195 @default.
• W2148525121 hasConcept C71924100 @default.
• W2148525121 hasConcept C86803240 @default.
• W2148525121 hasConcept C95444343 @default.
• W2148525121 hasConcept C97029542 @default.
• W2148525121 hasConceptScore W2148525121C126322002 @default.

• next